Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

(2019) Danny Rischin et al.   JOURNAL OF CLINICAL ONCOLOGY

Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies

(2018) Cássia Rita Pereira da Veiga et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Health Care Spending in the United States and Other High-Income Countries

(2018) Irene Papanicolas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Role of Immunotherapy in Head and Neck Cancer

(2018) Diane C. Ling et al.   SEMINARS IN RADIATION ONCOLOGY

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Cost-effectiveness of nivolumab in the treatment of head and neck cancer

(2018) A. Hirschmann et al.   ORAL ONCOLOGY

Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

(2017) Kathryn R Tringale et al.   JNCI-Journal of the National Cancer Institute

Cost‐Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma

(2017) Mahdi Zargar et al.   ONCOLOGIST

Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆

(2017) Matthew C. Ward et al.   ORAL ONCOLOGY

Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

(2017) Kathryn R Tringale et al.   JNCI-Journal of the National Cancer Institute

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

(2016) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare

(2016) Pricivel Carrera et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Cost–effectiveness thresholds in the USA: are they coming? Are they already here?

(2016) Robert W Dubois   Journal of Comparative Effectiveness Research

Measuring the Value of Prescription Drugs

(2015) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic overview of cost–effectiveness thresholds in ten countries across four continents

(2015) Ruth Schwarzer et al.   Journal of Comparative Effectiveness Research

Thresholds for the cost–effectiveness of interventions: alternative approaches

(2015) Elliot Marseille et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis

(2014) Nadarajah Vigneswaran et al.   Oral and Maxillofacial Surgery Clinics of North America

Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US

(2014) Allison Perrin et al.   JOURNAL OF MEDICAL ECONOMICS

Statistical issues and challenges in immuno-oncology

(2013) Tai-Tsang Chen   Journal for ImmunoTherapy of Cancer

Patients Value Metastatic Cancer Therapy More Highly Than Is Typically Shown Through Traditional Estimates

(2012) Seth A. Seabury et al.   HEALTH AFFAIRS

Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients

(2012) T. Kim Le et al.   JOURNAL OF MEDICAL ECONOMICS

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE